Business Of Biotech Engineering B Cells With Immusoft's Sean Ainsworth
5 snips
Dec 8, 2025 Sean Ainsworth, CEO and Chairman of Immusoft, shares his experiences transitioning from a lab to biotech entrepreneurship. He discusses the promise of engineered B cell therapies for lysosomal storage diseases, highlighting the benefits over traditional enzyme replacement therapies. Ainsworth delves into his journey through M&A, the future of gene therapies, and regulatory frameworks. He also elaborates on the streamlined patient experience of his therapies, aiming for safer, redosable options, and advancing candidate indications.
AI Snips
Chapters
Transcript
Episode notes
Early Startup Exit From University IP
- Sean founded Compendia Bioscience from university IP and sold it to Thermo Fisher for $50M.
- They raised little capital and achieved revenue early, which helped the exit.
Optogenetics Company Led To Major Acquisition
- Sean launched RetroSense using optogenetics IP from Wayne State and dosed its first patient.
- Allergan acquired the company after clinical dosing based on encouraging early data.
Always Build Toward An Exit
- Build your company with an exit in mind by engaging industry early and often.
- Use board and conference introductions to familiarize potential acquirers with your progress.